References
- Ulrich C M, Bigler J, Potter J D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130–140
- Lu D, Zhao Y, Tawatao R, Cottam H B, Sen M, Leoni L M, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118–3123
- Hedvat M, Jain A, Carson D A, Leoni L M, Huang G, Holden S, et al. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell 2004; 5: 565–574
- Yasui H, Hideshima T, Hamasaki M, Roccaro A M, Shiraishi N, Kumar S, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 2005; 106: 706–712
- Robak P, Linke A, Cebula B, Robak T, Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2006; 47: 2625–2634
- Jenson M, Engert A, Goebeler M E, Weissinger F, Wilhelm M, Osterborg A, et al. A novel pro-apoptotic agent SDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Blood 2003; 102: 674A
- Grosch S, Maier T J, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736–747
- Boon E M, Keller J J, Wormhoudt T A, Giardiello F M, Offerhaus G J, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004; 90: 224–229